4/A: Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth Hougen Corrects Stock Sale Reporting
SEC Form 4/A
Elizabeth Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals, amends a previous Form 4 filing to correct the number of shares sold on February 2, 2024.
Summary
- Elizabeth Hougen, the EVP, Finance & CFO of Ionis Pharmaceuticals, filed an amended Form 4 to correct a previous transaction.
- The amendment corrects the number of shares sold on February 2, 2024.
- The corrected filing shows that 2,162 shares of common stock were sold at a weighted average price of $49.5399.
- Following the transaction, Ms. Hougen beneficially owns 92,868 shares of Ionis Pharmaceuticals.
- The shares were sold in multiple transactions at prices ranging from $49.53 to $49.55 inclusive.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a previous error, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider trading activity, which is common for executives of publicly traded companies.
Stakeholder Impact
- The correction ensures transparency for shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date of original Form 4 filing and the stock sale transaction. |
| 09/04/2024 | Date of the amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.